DWA
SYRE icon

Dorsey Wright & Associates’s Spyre Therapeutics SYRE Stock Holding History

Dorsey Wright & Associates’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-46
Closed -$11K – 358
2020
Q2 		$11K Buy
+46
New +$8.76K ﹤0.01% 229
2019
Q2 		– Sell
-33
Closed -$7K – 335
2019
Q1 		$7K Sell
33
-32
-49% -$6.67K ﹤0.01% 270
2018
Q4 		$12K Buy
65
+11
+20% +$2.33K ﹤0.01% 252
2018
Q3 		$13K Buy
+54
New +$12.6K ﹤0.01% 251

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dorsey Wright & Associates's SYRE Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Spyre Therapeutics (SYRE) in Q3 2020, closing a stake of 46 shares — an estimated $11K sold.

Dorsey Wright & Associates first reported a position in SYRE in Q3 2018 and held it in 4 quarters. The position peaked at $13K in Q3 2018. 94 funds tracked by Wall St. Rank hold SYRE as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Spyre Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 46 Spyre Therapeutics shares in Q3 2020, an estimated $11K.
  • Dorsey Wright & Associates first reported a position in Spyre Therapeutics in Q3 2018 and held it in 4 quarters.
  • Dorsey Wright & Associates's Spyre Therapeutics position peaked at $13K in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.